Sittard/Leiden, The Netherlands, June 5, 2007 - Royal DSM N.V. and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing deal with Goettingen, Germany-based Sartorius Biotech GmbH. Sartorius will use Crucell's key technology to evaluate monoclonal antibodies produced using PER.C6® cells for calibrating and testing equipment products useful in the manufacture and/or purification of recombinant monoclonal antibodies. Crucell and Sartorius further agreed to expand their PER.C6® collaboration by sharing technology and data on antibody production. Financial details were not disclosed.
